HIV-1 infection and antiretroviral treatment optimisation
Societa Italiana Di Malattie Infettive E Tropicali SIMIT focuses on HIV-1 in individuals who have achieved virological suppression on integrase strand transfer inhibitor-based first-line therapy. Its research activity centres on treatment strategies for people living with HIV who are stable on suppressive regimens and may be considered for therapeutic simplification.
- Virologically suppressed HIV-1
- INSTI-based antiretroviral therapy
- Treatment simplification
The sponsor’s clinical interest lies in maintaining viral control while evaluating whether a switch to a streamlined antiretroviral regimen can support ongoing management of chronic HIV infection.
Dual-drug maintenance therapy
Its funded research includes the use of dolutegravir and lamivudine as a two-drug maintenance option for participants who recently achieved suppression on a three-drug regimen. This reflects a therapeutic focus on reducing treatment complexity in carefully selected patients with controlled HIV-1 RNA.
- Dolutegravir/lamivudine
- Two-drug regimen
- Maintenance antiretroviral therapy
The research area is centred on preserving virologic suppression while assessing the suitability of a simpler oral regimen in routine HIV care.
Virologic rebound and long-term suppression
The sponsor’s trial portfolio addresses the risk of virologic rebound after a treatment switch, with attention to sustained suppression over extended follow-up. This area is tied to the clinical monitoring of HIV-1 RNA in patients transitioning between suppressive regimens.
- Virologic rebound
- HIV-1 RNA monitoring
- Durable viral suppression
Its interest extends to the stability of treatment response in people with recent suppression on first-line antiretroviral therapy.
Adult infectious disease care in specialised treatment settings
As a laboratory and research organisation in Italy, SIMIT is involved in infectious disease research with a strong emphasis on HIV medicine. The active study network includes multiple collaborating sites, supporting clinical evaluation in a specialised care environment.
- Infectious diseases
- Specialist HIV care
- Collaborative clinical sites
Its current research activity is concentrated on therapeutic decision-making for adults with controlled HIV-1 infection receiving modern antiretroviral treatment.
